Literature DB >> 6286705

Determination of IgG- and IgM-class antibodies to mumps virus by solid-phase enzyme immunoassay.

O Meurman, P Hänninen, R V Krishna, T Ziegler.   

Abstract

An indirect enzyme immunoassay (EIA) for the determination of IgG and IgM antibodies to mumps virus is described. Viral antigens and control antigens were adsorbed onto polystyrene microtiter plates, and antibodies attached to the antigens were detected by subsequent binding of commercial peroxidase-labeled antibodies to the heavy chains of human IgG and IgM immunoglobulins. A comparison of antibody titers obtained by the EIA and by indirect immunofluorescence test showed a close concordance between these two tests, with EIA, however, being more sensitive. Occasional cross-reactions between mumps and parainfluenza antibodies were detected in the IgG antibody test but not in the IgM antibody test. In sera from 84 patients with mumps infection, all cases were diagnosed by the EIA IgM antibody assay, 96% from the first serum specimen. Mumps was diagnosed by complement fixation (CF) in 71% of these cases: unclear or erroneous results with parainfluenza titer increases in 10% and no diagnosis in 18% of the cases. The EIA IgM antibody assay was thus better than the CF test for the diagnosis of acute mumps infection.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6286705     DOI: 10.1016/0166-0934(82)90071-4

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  15 in total

1.  Evaluation of different continuous cell lines in the isolation of mumps virus by the shell vial method from clinical samples.

Authors:  J Reina; F Ballesteros; M Mari; M Munar
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

2.  Comparison between indirect immunofluorescence assay and shell vial culture for detection of mumps virus from clinical samples.

Authors:  Jordi Reina; Francisca Ballesteros; Enrique Ruiz de Gopegui; Maria Munar; Margarita Mari
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

3.  Comparison of a neutralization enzyme immunoassay and an enzyme-linked immunosorbent assay for evaluation of immune status of children vaccinated for mumps.

Authors:  T Harmsen; M C Jongerius; C W van der Zwan; A D Plantinga; C A Kraaijeveld; G A Berbers
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

4.  In vitro secondary generation of cytotoxic T lymphocytes in mice with mumps virus and their mumps-specific cytotoxicity among paramyxoviruses.

Authors:  Y Hosaka; Y Yasuda; O Seriburi; M G Moran; K Fukai
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

Review 5.  Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic Diversity.

Authors:  Eugene Lam; Jennifer B Rosen; Jane R Zucker
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

6.  Dot immunobinding assay for simultaneous detection of specific immunoglobulin G antibodies to measles virus, mumps virus, and rubella virus.

Authors:  F Condorelli; T Ziegler
Journal:  J Clin Microbiol       Date:  1993-03       Impact factor: 5.948

7.  Enzyme-linked immunosorbent assay compared with neutralization tests for evaluation of live mumps vaccines.

Authors:  H Sakata; M Hishiyama; A Sugiura
Journal:  J Clin Microbiol       Date:  1984-01       Impact factor: 5.948

8.  Assay of measles virus IgM and IgG class antibodies by use of peroxidase-labelled viral antigens.

Authors:  J Salonen; R Vainionpää; P Halonen
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

9.  Time-resolved fluoroimmunoassay with monoclonal antibodies for rapid diagnosis of influenza infections.

Authors:  H H Walls; K H Johansson; M W Harmon; P E Halonen; A P Kendal
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

10.  Amount and avidity of salivary and serum antibodies against Streptococcus mutans in two groups of human subjects with different dental caries susceptibility.

Authors:  O P Lehtonen; E M Gråhn; T H Ståhlberg; L A Laitinen
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.